- Home
- CYCU vs TPST Comparison
CYCU vs TPST Comparison
Compare CYCU & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CYCU | TPST |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 14.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CYCU | TPST |
|---|---|---|
| Price | $3.45 | $2.97 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | ★ 2.0M | 242.3K |
| Earning Date | 11-14-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,667,874.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.15 | $3.00 |
| 52 Week High | $2,045.10 | $13.65 |
Technical Indicators
Market Signals| Indicator | CYCU | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 25.03 |
| Support Level | $3.15 | $3.04 |
| Resistance Level | $4.40 | $3.23 |
| Average True Range (ATR) | 0.42 | 0.21 |
| MACD | -0.15 | 0.16 |
| Stochastic Oscillator | 16.79 | 15.10 |
Price Performance
Historical ComparisonAbout CYCU Cycurion Inc.
Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.